By Devika Patel
Knoxville, Tenn., May 26 - Anadys Pharmaceuticals, Inc. arranged a $12.5 million registered direct offering of stock, according to a prospectus supplement filed with the Securities and Exchange Commission.
The company will sell 5,813,954 common shares at $2.15 per share.
Lazard Capital Markets LLC is the lead placement agent, and Piper Jaffray & Co. is co-agent.
Settlement is expected June 1.
Proceeds will be used for general corporate purposes, including clinical trial expenses, research and development expenses, working capital and general and administrative expenses.
Anadys is a San Diego-based biopharmaceutical company developing novel medicines for the treatment of hepatitis C.
| Issuer: | Anadys Pharmaceuticals, Inc.
|
| Issue: | Common shares
|
| Amount: | $12.5 million
|
| Units: | 5,813,954
|
| Price: | $2.15
|
| Warrants: | No
|
| Agents: | Lazard Capital Markets LLC (lead), Piper Jaffray & Co.
|
| Pricing date: | May 26
|
| Settlement date: | June 1
|
| Stock symbol: | Nasdaq: ANDS
|
| Stock price: | $2.23 at close May 25
|
| Market capitalization: | $89.3 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
